About adalimumab
Tumor necrosis factor inhibitor
Used for
- Rheumatoid arthritis and juvenile idiopathic arthritis
- Psoriatic arthritis and ankylosing spondylitis
- Plaque psoriasis and hidradenitis suppurativa
- Crohn’s disease and ulcerative colitis
Usual adult dose
Usually 40 mg injected under the skin every other week; schedules vary by condition.
Usual dose in children
For juvenile arthritis, usually 20 or 40 mg every other week, based on weight; other uses have age-specific regimens.
Common side effects
- Injection-site reactions
- Upper respiratory infections
- Headache
- Rash
Important warnings
- Can cause serious infections, including tuberculosis; screening is needed before treatment.
- May reactivate hepatitis B; screening is recommended.
- Rarely causes lymphoma or other cancers, especially with additional immune-suppressing medicines.
- Avoid live vaccines during treatment.
Pregnancy
May be used when clinically needed; treatment decisions should consider disease control and possible transfer to the newborn late in pregnancy.
Breastfeeding
Generally considered compatible; discuss the infant’s health and treatment plan with a healthcare professional.
Interactions
- Live vaccines
- Other biologic immune-suppressing medicines
- Anakinra or abatacept
- Warfarin and theophylline levels may require monitoring
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.